

Presentation 2024 Results



September 24, 2024

Inpart Summit User Group Meeting Sarah Issa Chief Marketing Officer | Inpart





Intro & Purpose

Survey highlights 2022-2024

2024 Ranking


A study to **support both sides**

Heads of M&A and BD departments from top pharma companies expressed problems and needs that all pointing to an underlying need for evolving information from and about biotechs.

Insights into biotech and their **deals can be game-changers** for top pharma partnering teams.

Biotechs shared frustrations around lack of information or alignment with pharma.

Gap that we wanted to explore.



Methodology

Survey Promotion

Connect & mailing lists

Biotech Clusters

Labiotech

Conferences (BIO, BIO Korea)

Interviews

10 biotechs (clients)

January

March

February

Survey Design

20+ Questions External experts Previous trends In 2024: created a Academic version of the survey Septem ber

Data Cleaning & Analysis

Compete submissions Verified participants


Report Release

Mailing lists Partners Clients

October


Survey Participation


Increased traction and Research Institutes version.





Report Reach

Over +1,000 downloads annually.











More than half of Biotechs feel that identifying innovation is the greatest challenge in the biopharma industry today. Pricing pressures was identified as the second greatest challenge (39%).

When it comes to Al impact, the vast majority of biotechs (80%) believe that it is likely to be positive.

2024Q: What is the greatest challenge to the biopharma industry today?



2024Q: What is the impact of AI on the industry?








Intro & Purpose


Survey highlights 2022-2024

2024 Ranking


2022Q: What's your primary reason for partnering?



2022Q: What's your primary reason for partnering?



2022Q: What's your preferred Deal Type?




Year on year, large pharma is the preferred partner type. However, VC's and midsize pharma are growing in popularity.


Biotechs report that **midsize pharma are** easier to approach than larger ones.

Research Institutes reported a similar partner profile: 82% want to work with Large companies 65% want to work with start-ups 54% with VCs

2024Q: Who's your preferred partner types? (multiple)



Q: What are the main roadblocks you face during each phase of a typical deal?



Q: What is the biggest challenge in finding industry partners to commercialize research at your institute?

Difficulty in Finding the Right Contact Person



Identifying the right match between assets and company's scope.

> Networking and relationshipbuilding challenges.

Misalignment Between Academia and Industry



Disconnect between Academic focus vs industry needs and timelines.

Risk Aversion from Industry Partners and preference for high TRL.

Lack of Feedback and Communication from Industry




Industry unresponsive to outreach.

Research Institutes expect feedback on triaging decisions from interested companies or, at least, confirmation of receipt and decision.

In 2024, **91% of biopharma companies rely primarily on conferences to connect with partners** and 58% reported it being the most successful channel for meeting partners.

Partnering events are equally popular for Academics. Company websites and digital platforms are the third most popular method to partner, with the latter growing in popularity (68% increase in 2024 for biotechs).

2024Q: What channels do you usually use to find partners?



78% partnering conferences

2022


International conferences are the most popular type and successful (65%) type of event for meeting partners.

49% of biotechs said that local ones are the least successful type of conference in their experience for meeting partners.

BIO International is the must-attend event of the year for 45% of biotechs that participate in partnering events.

Both Academics and Biotechs reported that even though conferences are the best way to meet partners, they are expensive and time-consuming.

2024Q: What type of partnering conference do you attend?



2024Q: Most popular conference


BIO International (45%)

More than **50% of biotechs send their meeting requests as soon as partnering platforms open**


and the majority write detailed messages to delegates from select companies that they want to meet with.

The vast majority (93%) of Institutes send very personalized and targeted meeting requests during conferences.


2024Q: When do you start sending meeting requests?




2024Q: How do you primarily proceed with meetings at partnering conferences?



2024Q: What key difficulties do you encounter pre-conference?



2024Q: What key difficulties do you encounter post-conference?



Large pharma only **accepts 20% of meeting requests**

19




Intro & Purpose


Survey highlights 2022-2024



Biotechs rate Transparency and Communication as the highest criteria in partners.



Academics rate **Impact of Science** as the highest criteria in partners.



inpart

	2024 overall rating				Biotechs	2024	overall rating		
1		3.61	J&J/ Janssen	208		3.66	Merck & Co.	152	
2		3.56	Merck & Co.	211		3.64	J&J/ Janssen	150	
3		3.46	Novo Nordisk	190		3.57	Eli Lilly	146	
4		3.44	Eli Lilly	201		3.54	Roche	150	
5		3.44	Boehringer Ingelheim	n 193		3.54	Novo Nordisk	143	
6		3.44	Roche	209		3.53	Boehringer Ingelheir	m 144	
7		3.42	AstraZeneca	196		3.52	AstraZeneca	146	
8		3.36	Pfizer	215		3.40	Pfizer	153	
9		3.34	Sanofi	199		3.37	Novartis	150	
10		3.32	Novartis	211		3.37	Sanofi	148	
	Overall mean: 3.27		#	# of respondents	Overall mean: 3.34			# of respondents	

62 Biotechs said that they've entered into a partnership with top pharma and rated overall AM experience 3.91/5. Oinpart

	2024 overa	ll ratii	ng		Biotechs	2024	overall rating		Aca	demics	202	24 overall rating		
1		3.61	J&J/ Janssen	208		3.66	Merck & Co.	152			3.53	J&J/ Janssen	58	
2		3.56	Merck & Co.	211		3.64	J&J/ Janssen	150			3.32	Merck & Co.	59	
3		3.46	Novo Nordisk	190		3.57	Eli Lilly	146			3.27	Pfizer	62	
4		3.44	Eli Lilly	201		3.54	Roche	150			3.25	Sanofi	51	
5		3.44	Boehringer Ingelhein	1 93		3.54	Novo Nordisk	143			3.21	Novo Nordisk	47	
6		3.44	Roche	209		3.53	Boehringer Ingelhein	n 144			3.20	Novartis	61	
7		3.42	AstraZeneca	196		3.52	AstraZeneca	146			3.18	Boehringer Ingelhei	im 49	
8		3.36	Pfizer	215		3.40	Pfizer	153			3.17	Roche	59	
9		3.34	Sanofi	199		3.37	Novartis	150			3.16	CSL	44	
10		3.32	Novartis	211		3.37	Sanofi	148			3.13	GSK	54	
	Overall mean: 3.27		#	of respondents	Overall mean: 3.34			# of respondents	Overal	l mean: 3.10			# of respondents	

62 Biotechs said that they've entered into a partnership with top pharma and rated overall AM experience 3.91/5.

inpart

2024 overall rating

1		3.61	J&J/ Janssen		208	
2		3.56	Merck & Co.		211	
3		3.46	Novo Nordisk		190	
4		3.44	Eli Lilly		201	
5		3.44	Boehringer Ingelhe	eim	193	
6		3.44	Roche		209	
7		3.42	AstraZeneca		196	
8		3.36	Pfizer		215	
9		3.34	Sanofi		199	
10		3.32	Novartis		211	
	Overall mean: 3.27			#ofr	respond	ents

62 Biotechs said that they've entered into a partnership with top pharma and rated overall AM experience 3.91/5.

Biotechs

"Focused interest"

"Great company, always provide feedback and interest in a timely manner."

"Responsive, give feedback; organized."

"Interactions with the oncology team have been delightful and clear."

"Somehow, they have managed to maintain relationships and close deals while doing a reorg. Their interests are clear."

"An innovation powerhouse"

"Frequent communication."

"Thoughtful. Involves scientists within oncology in early discussions."

"I am unclear of their strategy."

"Difficult to receive feedback."

"Too often hard to contact or engage with."

Academics

"Responsive, once you find the right contact (challenging)."

"Clear vision, good feedback, robust science knowledge."

"The company negotiator had knowledge and authority to find mutually-acceptable deal terms."

"Very responsive, inquisitive and ready to move fast."

"My favorite company to work with [...] considerate about the university's needs and constraints".

"Excellent university liaison--responsive and takes the time to follow up without prompting."

"Totally non-responsive."

"Quite hierarchical but will move fast if there is strategic alignment."

"Difficult to understand exactly what they may be interested in.."

"Stop-and-go negotiations (so, no contact and then urgency)."